Precision radiation plus immunotherapy shows promise for bile duct cancer
NCT ID NCT07291947
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new approach for advanced bile duct cancer, combining a precise type of radiation (PULSAR) with immunotherapy drugs and chemotherapy. The goal is to see if this combination is safe and effective. The trial is recruiting 60 adults aged 18-75 with confirmed bile duct cancer that has spread.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Iparomlimab and Tuvonralimab Injection (QL1706) combined with chemotherapy and PULSAR radiation therapy
What this could lead to
If successful, this could offer a new treatment option for advanced bile duct cancer by combining precise radiation with immune-boosting drugs.
What could go wrong
This is an early-phase trial with only 60 participants, so results may not apply to all patients. The combination therapy may cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital
RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••